Brigham and Women's Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (11)

2023

  1. Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials

    International Journal of Cardiology, Vol. 377, pp. 86-88

2020

  1. Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers

    Open Heart, Vol. 7, Núm. 1

2017

  1. Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy

    Open Heart, Vol. 4, Núm. 2

2015

  1. Diltiazem treatment for pre-Clinical hypertrophic cardiomyopathy sarcomereMutation carriers: A pilot randomized trial to modify disease expression

    JACC: Heart Failure, Vol. 3, Núm. 2, pp. 180-188

2013

  1. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy

    Circulation: Cardiovascular Imaging, Vol. 6, Núm. 3, pp. 415-422

2011

  1. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)

    Kidney International

2010

  1. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy

    New England Journal of Medicine, Vol. 363, Núm. 6, pp. 552-563

  2. The authors reply

    New England Journal of Medicine

2006

  1. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: Implications for clinical and subclinical atherosclerosis

    Journal of the American College of Cardiology, Vol. 47, Núm. 7, pp. 1369-1378

2002

  1. Pathophysiologic and therapeutic importance of tissue ACE: A consensus report

    Cardiovascular Drugs and Therapy, Vol. 16, Núm. 2, pp. 149-160

2001

  1. The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data

    American Journal of Cardiology, Vol. 88, Núm. 9 SUPPL. 1, pp. 1-20